Skip to main content
Premium Trial:

Request an Annual Quote

NCI Expands Seven Bridges' Cancer Genomics Cloud Pilot Contract

NEW YORK (GenomeWeb) – Seven Bridges announced today that its contract with the National Cancer Institute's Cancer Genomics Cloud Pilots program has been expanded to include the addition of new data sources, better integration with the institute's Genomic Data Commons, and improved usability.

In early 2014, the NCI launched an initiative to build a network of genomic data repositories that can be securely and easily accessed by the broader cancer research community. As part of this effort, it awarded contracts to Seven Bridges and other organizations in 2015 to develop pilots — infrastructures and sets of tools for accessing, exploring, and analyzing molecular data. 

Seven Bridges' pilot, which launched in February, provides access to The Cancer Genome Atlas (TCGA), as well as computational and data-analysis tools. With the contract extension, the company said its pilot will be expanded to include the NCI's Genomic Data Commons, which will allow researchers to access and analyze data from additional cancer genome programs including data on pediatric cancers through the Therapeutically Applicable Research to Generate Effective Treatments program and the Cancer Genome Characterization Initiative.

Seven Bridges will also integrate other data repositories into the pilot s — including ones containing genomic, imaging, and proteomics datasets — and will work to improve the system's overall usability.
"Our vision for the Cancer Genomics Cloud has always been about giving as many researchers as possible useful access to cancer genomic data, by putting it alongside the computational tools they need to make new strides in cancer research," Brandi Davis-Dusenbery, senior vice president of science and product at Seven Bridges, said in a statement. "We are delighted to continue working to expand both the reach and the scope of the Cancer Genomics Cloud to include more data sets and support more users, ultimately accelerating the progress of precision treatments for cancer."